Anna Rivera/LinkedIn
Jun 2, 2026, 17:55
Anna Rivera: Hemophilia Management – A Shift from Traditional IV Therapies to Novel Subcutaneous Agents
Anna Rivera, Director of Operations at Rx Relief, shared a post on LinkedIn:
“Hemophilia management is undergoing a shift from traditional IV therapies to novel subcutaneous agents.
As these advanced therapies emerge, the clinical pharmacist’s role in protocol development and patient education is vital.”
Stay updated with Hemostasis today.
-
Jul 26, 2026, 01:48Rob Maloney: Why Global Diagnosis is the Missing Piece in Bleeding Disorder Care
-
Jul 26, 2026, 01:35Moustafa Abdou: Ehlers-Danlos Syndrome – Why Collagen Matters for Hemostasis
-
Jul 26, 2026, 01:25Vrisha Shah: Exploring Transgenic Mouse Models for Pregnancy Outcomes at ISTH 2026
-
Jul 26, 2026, 01:06Christine Bork: Why Misinformation Around a Single Vitamin Postpartum is Putting Babies at Risk
-
Jul 26, 2026, 00:44A Significant Step Forward For People With Bleeding Disorders In The Dominican Republic – WFH
-
Jul 25, 2026, 18:00The Evolving Landscape of Factor Replacement Therapy – EAHAD
-
Jul 25, 2026, 17:43Heghine Khachatryan: Advancing Care for Women and Girls With Hemophilia
-
Jul 25, 2026, 17:00Revathy R Menon: A Memorable Milestone at the 39th ISBT Congress
-
Jul 25, 2026, 16:19Nicola Potere: From Scientific Exchange to Global Collaboration at ISTH 2026